Skip to main content

and
  1. No Access

    Article

    The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent

    G Kong, Y-I Chang, X You, E A Ranheim, Y Zhou, C E Burd, J Zhang in Leukemia (2016)

  2. No Access

    Article

    Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis

    Despite the well-established role of oncogenic RAS in promoting tumor formation, whether and how wild-type (WT) Ras inhibits tumorigenesis under physiological conditions remains controversial. Here, we show that ...

    G Kong, Y-I Chang, A Damnernsawad, X You, J Du, E A Ranheim, W Lee, M-J Ryu in Leukemia (2016)

  3. No Access

    Article

    Loss of Dnmt3a and endogenous KrasG12D/+ cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis

    Oncogenic NRAS and KRAS mutations are prevalent in human juvenile and chronic myelomonocytic leukemia (JMML/CMML). However, additional genetic mutations cooperating with oncogenic RAS in JMML/ CMML progression an...

    Y-I Chang, X You, G Kong, E A Ranheim, J Wang, J Du, Y Liu, Y Zhou, M-J Ryu in Leukemia (2015)

  4. Article

    Open Access

    Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C

    A K Erbe, Wei Wang, B Grzywacz, E A Ranheim in Journal for ImmunoTherapy of Cancer (2013)

  5. No Access

    Article

    Juvenile syndecan-1 null mice are protected from carcinogen-induced tumor development

    We previously showed that mice with a null mutation in syndecan-1 (Sdc1; CD138) were resistant to Wnt1-induced mammary tumor initiation. The absence of Sdc1 inhibited the increase in the mammary stem cell frac...

    S P McDermott, E A Ranheim, V S Leatherberry, S S Khwaja, K S Klos in Oncogene (2007)